1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Bivision

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2021

Location

Shanghai China

Primary Industry

Biotechnology

About

Based in Shanghai, China, and founded in 2021, Bivision is a biopharmaceutical developer focused on developing next-generation targeted radionuclide therapies that are image-guided and integrate diagnosis and treatment. The company's co-founder, Haihua Yu, is a PhD in Medicinal Chemistry, Fudan University. In December 2023, its drug, JH02, completed Phase I clinical trials. In July 2024, Bivision closed a series A funding co-led by Golden China Fund and Huajin Dadao Investment. Bivision has three major technology platforms which are targeted ligand screening, radioactive drug conjugation, and drug clinical transformation. The company's technology platforms can be used for ligand screening, modulation of coupling factors (J-Linker) and clinical transformation. Its product pipeline includes JH002, JH003, JH004, N001 and N002. The drugs can be used to treat cancer. The company generates revenue by developing drugs that can be used to treat cancer.
Current Investors
Kaitai Capital, Gaorong Ventures, Virtus Inspire Ventures

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Healthcare IT, Oncology/Cancer Treatment
Website
www.bivisionpharma.com
Verticals
HealthTech, Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.